Testosterone-boosting medications and cardiovascular risk - a systematic review and meta-analysis

January 2015

Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis. Corona G, Maseroli E, Rastrelli G, et al. Expert opinion on drug safety. Oct 2014;13(10):1327-1351.

Accumulating evidence shows beneficial effects of testosterone therapy on a wide range of health outcomes, including inflammation, insulin sensitivity, muscle mass, body fat mass, lipid profiles, endothelial function, bone mineral density, energy and vitality, mood, sexual function and overall quality of life.1-9 Despite this, concerns have been raised that testosterone therapy could have detrimental effects on cardiovascular disease.

This editorial summarizes results from a comprehensive systematic review and meta-analysis, the largest to date, of all placebo-controlled randomized clinical trials (RCTs) on the effect of testosterone therapy on cardiovascular-related problems.10


  • This analysis, performed on the largest number of studies collected so far, indicates that testosterone therapy is not related to any increase in cardiovascular risk, even when composite or single adverse events were considered.
  • Present data do not support a causal role between testosterone therapy and cardiovascular events.
  • In studies performed in subjects with metabolic derangements a protective effect of testosterone therapy on cardiovascular risk was observed.
  • Testosterone therapy in hypogonadal men can be a valuable strategy to improve metabolic profile, reduce body fat and increase lean muscle mass, which would ultimately reduce the risk of heart disease.
  • No sponsorship bias was detected, because no difference in MACE risk was found when the analysis was performed according to the presence or absence of drug company financing.
  • This new systematic review and meta-analysis of randomized controlled trials reporting the effects of testosterone therapy on different cardiovascular outcomes, included 75 RCTs with a total of 3016 patients on testosterone therapy and 2448 patients on placebo, for mean duration of 34 weeks.
  • The principal outcome of this analysis was the effect of testosterone therapy, as compared with placebo, on the incidence of new major adverse cardiovascular events (MACE). MACE was defined as the composite of cardiovascular death, non-fatal acute myocardial infarction and stroke, and acute coronary syndromes and/or heart failure reported as serious adverse events. This was done to comply with requirements for drug safety assessment, as required by regulatory agencies.
  • The meta-analysis took into consideration hypogonadism status (total testosterone levels < 12 nmol/L and mixed baseline testosterone levels), trial duration (≤ 12 weeks and > 12 weeks), clinical conditions (elderly men, men with cardiovascular disease, frail men and men with metabolic diseases) and industry-funding vs. non-industry-funding.
  • The mean age, baseline testosterone level and body mass index (BMI) of enrolled patients were 59.9 years, 11.2 nmol/L (323 ng/dL) and 28.1 kg/m2.
  • Testosterone was administered in different doses, formulations (oral, intramuscular and transdermal testosterone preparations) and in mixed populations of hypogonadal/eugonadal subjects.

What is known

The notion that testosterone is "bad for the heart" arose from the well documented simple observation that heart diseases are more prevalent in men than in women.11-18 Acute coronary heart disease and ischaemic stroke events appear approximately 10 years earlier in men than in women, and these rates remain higher in men than in women in all age groups.11 More men are living with and dying of coronary heart disease than women, and have more hospital discharges for cardiovascular diseases, and the prevalence of coronary heart disease is higher in men within each age stratum.19 These observations contributed to the perception that heart disease is a “man’s disease”.19

A recent analysis found that the age-standardized risk of death from cardiovascular diseases is 80% higher for men (442/100,000) than for women (246/100,000).12 Because men have higher testosterone, it was automatically assumed that testosterone may be the culprit. Further support for this notion comes from case reports of sudden cardiovascular death amongst male athletes abusing anabolic steroids (which are synthetic compounds similar to testosterone)20-24, and observations that testosterone dose-dependently increases hematocrit25,26 and reduces HDL-cholesterol at supra-physiological levels.27-29

However, longitudinal observational studies demonstrate that it is reduced, rather than increased testosterone levels, which are associated with elevated risk of cardiovascular disease, cardiovascular mortality and all-cause mortality.30,31 This can be explained by the well documented strong associations of hypogonadism with a number of cardiovascular risk factors, including adiposity and increased waist circumference, insulin resistance and type 2 diabetes mellitus, hypertension and inflammation.32-37

In line with this, androgen deprivation therapy for prostate cancer causes worsening of these risk factors and co-morbidities38, and a growing body of research demonstrates that testosterone therapy improves them.1-9,39 This indicates that hypogonadism is causally related to disease development and progression.

What this study adds

The results from the comprehensive systematic review and meta-analysis presented here show that testosterone therapy is not related to any increase in cardiovascular risk, and that it may have a protective effect on cardiovascular risk in men with metabolic derangements.10 This conclusion is based on an analysis of the largest number of studies collected so far, which clearly refutes the previously purported causal role between testosterone therapy and cardiovascular events.

A strength of this meta-analysis is that its principal outcome was the effect of testosterone therapy, as compared with placebo, on the incidence of new major adverse cardiovascular events (MACE).10 A previous meta-analysis, which concluded that testosterone therapy increased the risk of cardiovascular-related events40, included many events which are not typically considered for the assessment of cardiovascular risk (e.g., peripheral edema, self-reported syncope etc.). This can be grossly misleading due to the limited reliability of diagnostic criteria used to attribute these events as drug-related. It should be recognized that the use of MACE, instead of a broader ambiguous definition of cardiovascular side effects, has the advantage of a clearer diagnostic definition and precise diagnosis, which is less dependent on investigators’ subjective opinions. Therefore, the assessments of cardiovascular safety of any therapy should be based on the incidence of MACE, which are easier to detect and less controversial in diagnosis. It should be underscored that regulatory agencies assessing the safety of drugs require analyses of MACE and not of broadly defined cardiovascular side effects.41

This meta-analysis also did not observe any sponsorship bias, because no difference in cardiovascular risk was found when the analysis was performed according to the presence or absence of drug company funding.10 This is also in contrast to the meta-analysis just mentioned, which reported that the effects of testosterone on cardiovascular-related events varied with source of funding.40

Comparison to previous meta-analyses

As of this writing, only one previous meta-analysis concluded that testosterone therapy increases the risk of cardiovascular-related events.40 However, this meta-analysis has been criticized on several grounds. The authors specifically included only studies in which cardiovascular events were reported; therefore studies without any cardiovascular events were excluded. Importantly, two studies were included that were performed with off-label use of the respective testosterone preparation42,43 and one study used a non-approved preparation of testosterone (oral micronised testosterone) which resulted in supraphysiologic serum testosterone levels reaching as high as 745 nmol/L (21,486 ng/dl), which is about 20 times the upper limit of normal.44 Since oral forms of testosterone may cause liver toxicity (comment: this only proven for the 7α-methylated testosterone preparations) it is no surprise that such markedly supraphysiologic testosterone would be harmful, especially in a study population of patients with liver cirrhosis.44

These three studies accounted for 39% of events in the testosterone treated group and 18% in the placebo group.44 After excluding them from the analysis, there would have been a similar rate of events among testosterone and placebo groups; 70/1570 (4.5%) events in the testosterone group and 53/1001 (5.3%) events in the placebo group.

Notably, results from three other large meta-analyses which included a more representative set of studies, and that specifically focused on identifying potential adverse effects of testosterone treatment, are in line with the conclusions from the most recent meta-analysis reported here; none of them found increased cardiovascular risks with testosterone therapy versus placebo.45-47 More specifically, their conclusions were:

  • The frequency of cardiovascular events, sleep apnea or death is not significantly different between the testosterone and placebo treated groups.45
  • Currently (as of 2007) available evidence weakly supports the inference that testosterone use in men is not associated with important cardiovascular effects.47
  • There is no significant negative effect of testosterone therapy on mortality, prostate, or cardiovascular outcomes.46

Supporting data from other studies

Multiple other lines of evidence concur with the conclusions in this meta-analysis. Two notable studies demonstrated that testosterone therapy decreases mortality compared with no testosterone treatment48, and improves survival in hypogonadal men with type 2 diabetes.49 Further support comes from The MrOS (Osteoporotic Fractures in Men) study which after a 5-year follow-up found that an apparent threshold of ≥550 ng/dL (approximately 19 nmol/L) needs to be reached in order to reduce risk of cardiovascular events.50 In this study, men in the highest quartile of testosterone (≥550 ng/dL) had a 30% lower risk of cardiovascular events (hazard ratio: 0.70) compared with men in the 3 lower quartiles, where no protective effect was noted.50 This association remained after adjustment for traditional cardiovascular risk factors and was not materially changed in analyses excluding men with known cardiovascular disease at baseline.50

Additional support refuting the notion that testosterone therapy would be pro-atherogenic comes from a notable recent dose-response study which assessed the effects of graded doses of testosterone on serum markers of oxidative stress, chemotaxis, adhesion, and inflammation in healthy younger and older men.51 Weekly injections of 25, 50, 125, 300, or 600 mg of testosterone enanthate were administered for 20 weeks in 121 eugonadal men (n = 61, 18-35 years of age and n = 60, 60-75 years of age). No significant linear associations were observed between testosterone dose and MCP-1 (chemokine monocyte chemotactic protein-1), sICAM-1 (soluble intracellular adhesion molecule-1), or hs-CRP (high-sensitivity C-reactive protein) (all p-trend >0.20).51 Also, levels of the oxidative stress marker 8-isoprostane PGF2-alpha (8-iso-PGF2-alpha) were not negatively impacted.51 As MCP-152, sICAM-153 and hs-CRP54 are atherogenic markers which independently predict risk of cardiovascular disease or acute myocardial infarction, the results from this study are strongly congruent with the conclusions that testosterone therapy does not increase atherosclerosis.


A few flawed studies of epidemiological observations induced an epidemic of sensational and misleading media coverage and false claims alleging potential dangerous effect of testosterone therapy on the cardiovascular system.55,56 Over the past year popular press headlines have purported that testosterone therapy is associated with serious cardiac hazards. However, as outlined here, results from RCTs, which are gold standard in medical research, show that testosterone therapy does not increase cardiovascular events, and to the contrary, that it is protective against cardiovascular events in hypogonadal men.10 According to expert opinion, testosterone therapy in hypogonadal men can be a valuable strategy to improve metabolic profile, reduce body fat and increase lean muscle mass, which would ultimately reduce the risk of heart disease.10


  • Francomano D, Ilacqua A, Bruzziches R, Lenzi A, Aversa A. Effects of 5-year treatment with testosterone undecanoate on lower urinary tract symptoms in obese men with hypogonadism and metabolic syndrome. Urology. Jan 2014;83(1):167−173. Return to content
  • Haider A, Meergans U, Traish A, et al. Progressive Improvement of T-Scores in Men with Osteoporosis and Subnormal Serum Testosterone Levels upon Treatment with Testosterone over Six Years. International journal of endocrinology. 2014;2014:496948. Return to content
  • Haider A, Saad F, Doros G, Gooren L. Hypogonadal obese men with and without diabetes mellitus type 2 lose weight and show improvement in cardiovascular risk factors when treated with testosterone: An observational study. Obes Res Clin Pract. Jul-Aug 2014;8(4):e339-349. Return to content
  • Haider A, Yassin A, Doros G, Saad F. Effects of long-term testosterone therapy on patients with "diabesity": results of observational studies of pooled analyses in obese hypogonadal men with type 2 diabetes. International journal of endocrinology. 2014;2014:683515. Return to content
  • Haider A, Zitzmann M, Doros G, Isbarn H, Hammerer P, Yassin A. Incidence of Prostate Cancer in Hypogonadal Men Receiving Testosterone Therapy: Observations from Five Year-median Follow-up of Three Registries. J. Urol. Jun 26 2014. Return to content
  • Saad F, Haider A, Doros G, Traish A. Long-term treatment of hypogonadal men with testosterone produces substantial and sustained weight loss. Obesity (Silver Spring). Oct 2013;21(10):1975−1981. Return to content
  • Traish AM, Haider A, Doros G, Saad F. Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long-term registry study. Int. J. Clin. Pract. Mar 2014;68(3):314−329. Return to content
  • Yassin A, Doros G. Testosterone therapy in hypogonadal men results in sustained and clinically meaningful weight loss. Clinical obesity. Jun 2013;3(3-4):73−83. Return to content
  • Traish AM. Outcomes of testosterone therapy in men with testosterone deficiency (TD): Part II. Steroids. Oct 2014;88C:117−126. Return to content
  • Corona G, Maseroli E, Rastrelli G, et al. Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis. Expert opinion on drug safety. Oct 2014;13(10):1327−1351. Return to content
  • Hyvarinen M, Qiao Q, Tuomilehto J, Soderberg S, Eliasson M, Stehouwer CD. The difference between acute coronary heart disease and ischaemic stroke risk with regard to gender and age in Finnish and Swedish populations. International journal of stroke: official journal of the International Stroke Society. Jun 2010;5(3):152−156. Return to content
  • Mikkola TS, Gissler M, Merikukka M, Tuomikoski P, Ylikorkala O. Sex differences in age-related cardiovascular mortality. PloS one. 2013;8(5):e63347. Return to content
  • Ng MK. New perspectives on Mars and Venus: unravelling the role of androgens in gender differences in cardiovascular biology and disease. Heart, lung & circulation. Jun 2007;16(3):185−192. Return to content
  • Perez-Lopez FR, Larrad-Mur L, Kallen A, Chedraui P, Taylor HS. Gender differences in cardiovascular disease: hormonal and biochemical influences. Reprod Sci. Jun 2010;17(6):511−531. Return to content
  • Phillips GB. Is atherosclerotic cardiovascular disease an endocrinological disorder? The estrogen-androgen paradox. J. Clin. Endocrinol. Metab. May 2005;90(5):2708−2711. Return to content
  • Rosano GM. Androgens and coronary artery disease. A sex-specific effect of sex hormones? Eur. Heart J. Jun 2000;21(11):868−871. Return to content
  • Seifarth JE, McGowan CL, Milne KJ. Sex and life expectancy. Gender medicine. Dec 2012;9(6):390−401. Return to content
  • Vitale C, Mendelsohn ME, Rosano GM. Gender differences in the cardiovascular effect of sex hormones. Nature reviews. Cardiology. Aug 2009;6(8):532−542. Return to content
  • Mosca L, Barrett-Connor E, Wenger NK. Sex/gender differences in cardiovascular disease prevention: what a difference a decade makes. Circulation. Nov 8 2011;124(19):2145−2154. Return to content
  • Payne JR, Kotwinski PJ, Montgomery HE. Cardiac effects of anabolic steroids. Heart. May 2004;90(5):473−475. Return to content
  • Nieminen MS, Ramo MP, Viitasalo M, et al. Serious cardiovascular side effects of large doses of anabolic steroids in weight lifters. Eur. Heart J. Oct 1996;17(10):1576−1583. Return to content
  • Baggish AL, Weiner RB, Kanayama G, et al. Long-term anabolic-androgenic steroid use is associated with left ventricular dysfunction. Circulation. Heart failure. Jul 2010;3(4):472−476. Return to content
  • Kersey RD, Elliot DL, Goldberg L, et al. National Athletic Trainers Association position statement: anabolic-androgenic steroids. Journal of athletic training. Sep-Oct 2012;47(5):567−588. Return to content
  • Rothman RD, Weiner RB, Pope H, et al. Anabolic androgenic steroid induced myocardial toxicity: an evolving problem in an aging population. BMJ case reports. 2011;2011. Return to content
  • Coviello AD, Kaplan B, Lakshman KM, Chen T, Singh AB, Bhasin S. Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. J. Clin. Endocrinol. Metab. Mar 2008;93(3):914−919. Return to content
  • Anderson RA, Ludlam CA, Wu FC. Haemostatic effects of supraphysiological levels of testosterone in normal men. Thromb. Haemost. Aug 1995;74(2):693−697. Return to content
  • Bhasin S, Woodhouse L, Casaburi R, et al. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab. Dec 2001;281(6):E1172−1181. Return to content
  • Singh AB, Hsia S, Alaupovic P, et al. The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men. J. Clin. Endocrinol. Metab. Jan 2002;87(1):136−143. Return to content
  • Bhasin S, Woodhouse L, Casaburi R, et al. Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle. J. Clin. Endocrinol. Metab. Feb 2005;90(2):678−688. Return to content
  • Corona G, Rastrelli G, Monami M, et al. Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. em>Eur. J. Endocrinol 31. Araujo AB, Dixon JM, Suarez EA, Murad MH, Guey LT, Wittert GA. Clinical review: Endogenous testosterone and mortality in men: a systematic review and meta-analysis. J. Clin. Endocrinol. Metab. Oct 2011;96(10):3007−3019. Return to content
  • Traish AM. Adverse health effects of testosterone deficiency (TD) in men. Steroids. Oct 2014;88C:106−116. Return to content
  • Traish AM, Miner MM, Morgentaler A, Zitzmann M. Testosterone deficiency. Am. J. Med. Jul 2011;124(7):578−587. Return to content
  • Ullah MI, Washington T, Kazi M, Tamanna S, Koch CA. Testosterone deficiency as a risk factor for cardiovascular disease. Horm. Metab. Res. Mar 2011;43(3):153−164. Return to content
  • Tsujimura A. The Relationship between Testosterone Deficiency and Mens Health. The world journal of mens health. Aug 2013;31(2):126−135. Return to content
  • Maggio M, Basaria S. Welcoming low testosterone as a cardiovascular risk factor. Int. J. Impot. Res. Jul-Aug 2009;21(4):261−264. Return to content
  • Yeap BB. Are declining testosterone levels a major risk factor for ill-health in aging men? Int. J. Impot. Res. Jan-Feb 2009;21(1):24−36. Return to content
  • Saylor PJ, Smith MR. Adverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancer. Journal of the National Comprehensive Cancer Network: JNCCN. Feb 2010;8(2):211−223. Return to content
  • Saad F, Aversa A, Isidori AM, Gooren LJ. Testosterone as potential effective therapy in treatment of obesity in men with testosterone deficiency: a review. Current diabetes reviews. Mar 2012;8(2):131−143. Return to content
  • Xu L, Freeman G, Cowling BJ, Schooling CM. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC medicine. 2013;11:108. Return to content
  • U.S. Food and Drug Administration (FDA). Available at: http://www.fda.gov Accessed Sept 29, 2014. Return to content
  • Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N. Engl. J. Med. Jul 8 2010;363(2):109−122. Return to content
  • Spitzer M, Basaria S, Travison TG, et al. Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a parallel, randomized trial. Ann. Intern. Med. Nov 20 2012;157(10):681−691. Return to content
  • Testosterone treatment of men with alcoholic cirrhosis: a double-blind study. The Copenhagen Study Group for Liver Diseases. Hepatology. Sep-Oct 1986;6(5):807−813. Return to content
  • Calof OM, Singh AB, Lee ML, et al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J. Gerontol. A. Biol. Sci. Med. Sci. Nov 2005;60(11):1451−1457. Return to content
  • Fernandez-Balsells MM, Murad MH, Lane M, et al. Clinical review 1: Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J. Clin. Endocrinol. Metab. Jun 2010;95(6):2560−2575. Return to content
  • Haddad RM, Kennedy CC, Caples SM, et al. Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin. Proc. Jan 2007;82(1):29−39. Return to content
  • Shores MM, Smith NL, Forsberg CW, Anawalt BD, Matsumoto AM. Testosterone treatment and mortality in men with low testosterone levels. J. Clin. Endocrinol. Metab. Jun 2012;97(6):2050−2058. Return to content
  • Muraleedharan V, Marsh H, Kapoor D, Channer KS, Jones TH. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur. J. Endocrinol. Dec 2013;169(6):725−733. Return to content
  • Ohlsson C, Barrett-Connor E, Bhasin S, et al. High serum testosterone is associated with reduced risk of cardiovascular events in elderly men. The MrOS (Osteoporotic Fractures in Men) study in Sweden. J. Am. Coll. Cardiol. Oct 11 2011;58(16):1674−1681. Return to content
  • Roberts CK, Chen BH, Pruthi S, Lee ML. Effects of varying doses of testosterone on atherogenic markers in healthy younger and older men. American journal of physiology. Regulatory, integrative and comparative physiology. Jan 15 2014;306(2):R118−123. Return to content
  • Deo R, Khera A, McGuire DK, et al. Association among plasma levels of monocyte chemoattractant protein-1, traditional cardiovascular risk factors, and subclinical atherosclerosis. J. Am. Coll. Cardiol. Nov 2 2004;44(9):1812−1818. Return to content
  • Ridker PM, Hennekens CH, Roitman-Johnson B, Stampfer MJ, Allen J. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet. Jan 10 1998;351(9096):88−92. Return to content
  • Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med. Mar 23 2000;342(12):836−843. Return to content
  • Finkle WD, Greenland S, Ridgeway GK, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PloS one. 2014;9(1):e85805. Return to content
  • Vigen R, ODonnell CI, Baron AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. Nov 6 2013;310(17):1829−1836. Return to content